NEW YORK, Oct. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=106639&from=4 CLASS PERIOD: January 23, 2023 to July 17, 2024A ...

NEW YORK, Oct. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024. Agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. and internationally. Among other product candidates, the Company is developing balstilimab, an anti-PD-1 antagonist th ...

NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?pri ...

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN). Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104517&from=3  CLASS PERIOD: January 23, 2023 to July ...

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).Shareholders who purchased shares of AGEN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/agenus-loss-submission-form/?id=104025&from=4CLASS PERIOD: January 23, 2023 to July 17, 2024 ...

Core Viewpoint - A class action has been filed against Agenus Inc. for allegedly misleading investors regarding the effectiveness and prospects of its drug candidates, particularly botensilimab and balstilimab, during the specified class period [1][2]. Group 1: Company Overview - Agenus Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology products, including balstilimab, an anti-PD-1 antagonist, and botensilimab, a CTLA-4 blocking antibody [1]. - The company is currently conducting Phase 2 clinical trials for both drug candidates, targeting second line cervical cancer and pancreatic cancer/melanoma, respectively [1]. Group 2: Allegations and Legal Action - The allegations state that Agenus failed to disclose that the combination therapy of botensilimab and balstilimab was less effective than claimed, leading to overstated clinical results and regulatory prospects [2]. - Following a press release on July 18, 2024, regarding the FDA's feedback on the drug combination, Agenus's stock price dropped by $10.43 per share, or 58.83%, closing at $7.30 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by November 5, 2024, although participation is not required to be eligible for recovery [4].

NEW YORK, Sept. 20, 2024 /PRNewswire/ --, September 20, 2024 – Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged securities fraud between January 23, 2023 and July 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/agenus-lawsuit-sub ...